On September 3, 2026 Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, reported that management will participate in a fireside chat at the 2026 Annual Cantor Global Healthcare Conference, being held September 9–12, 2026 in New York, NY. Discussion topics will include an overview of the differentiated and favorable tolerability and meaningful clinical activity seen with FT819, the Company’s off-the-shelf CAR T-cell product candidate for the treatment of various autoimmune diseases. The conversation will also focus on the commencement of RECLAIM-LN, the Phase 2 potentially registrational trial in lupus nephritis, as well as the unique safety elements that are incorporated into the design of FT819. Management will also host one-on-one meetings with investors during the conference.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
2026 Annual Cantor Global Healthcare Conference
Date: Wednesday, September 9, 2026
Time: 9:45 a.m. EDT
Location: New York, NY
Webcast: Fate Fireside Chat
An archived replay of the webcast will be available for 30 days on the Company’s website following the event under "Events & Presentations" in the Investors section of the Company’s website at www.fatetherapeutics.com.
(Press release, Fate Therapeutics, SEP 3, 2026, View Source [SID1234670571])